PHARMACY

FDA approves Lev Pharmaceuticals’ Cinryze for treatment of hereditary angioedema

BY Alaric DeArment

NEW YORK The Food and Drug Administration has approved a drug for protecting patients with hereditary angioedema from angioedema attacks.

Lev Pharmaceuticals announced Friday that the FDA had approved the drug Cinryze C1 inhibitor as a routine protection against the attacks.

The biotech company said it expects the drug to become commercially available later this year.

Hereditary angioedema, also known as HAE, is a rare genetic disorder resulting from deficiency of the C1 inhibitor, a human plasma protein. The disease causes recurrent, unpredictable and potentially life-threatening inflammation attacks affecting the larynx, abdomen, face, arms and legs and urogenital tract. About 10,000 Americans have the disease and must spend 20 to 100 days a year incapacitated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Shopko donates school supplies to Green Bay area elementary school

BY Alaric DeArment

GREEN BAY, Wis. An elementary school in Green Bay received a variety of school supplies from a locally headquartered retail chain.

Shopko announced Oct. 2 that it had donated the supplies to Sunrise River Elementary, which serves students in second through fifth grade. The supplies included basic items from the school’s required supply list.

Shopko operates stores throughout the Midwest and West.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ARCA Biopharma makes unprecedented payment to Aeolus following FDA approval of bucindolol

BY Alaric DeArment

NEW YORK Aeolus Pharmaceuticals announced Friday that it had received a $175,000 milestone payment from ARCA Biopharma following the Food and Drug Administration’s acceptance of an approval application for a cardiovascular drug.

Aeolus said the drug, bucindolol, could be the first genetically targeted cardiovascular therapy. CPEC, a company owned jointly by Aeolus and Indevus Pharmaceuticals, licensed all rights to bucindolol to ARCA.

“ARCA’s success in demonstrating the potential benefits of bucindolol in treating heart failure in patients is encouraging,” Aeolus president and chief executive officer John McManus said in a statement. “We look forward to an expeditious review and hope for a positive outcome.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?